TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03410875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Eligible patients will receive vemurafenib at a dose of 960mg orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles. In case of certain defined toxicities, dose reductions of vemurafenib by 50% (480mg b.i.d.) or interruptions of up to 15 days are permitted. If additional dose reduction is required, vemurafenib may be reduced to 240mg oral b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks. Obinutuzumab infusions will be administered at 1000mg per day on days 1, 8 and 15 during the cycle 2 and 1000mg per day every 4 weeks during the cycle 3 and 4 of treatment.
Study: NCT02744677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3/SAPIEN 3 Ultra RESILIA THV
Description: SAPIEN 3/SAPIEN 3 Ultra RESILIA THV in the pulmonic position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 THV
Description: SAPIEN 3 THV in the pulmonic position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 Ultra RESILIA THV
Description: SAPIEN 3 Ultra RESILIA THV in the pulmonic position
Study: NCT04236453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cobicistat
Description: Participant will receive a single dose of Cobicistat tablet orally on Day 1.
Study: NCT04928586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DMARDs
Description: CTD-ILD patients treated with DMARDs according to the condition of the disease
Study: NCT02242110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERRT-Bipolar Disorder
Description: The nightmare treatment, called Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder, is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
Study: NCT02817204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
Study: NCT02162979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: sildenafil 50mg BID for 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01668069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
Study: NCT00474253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: Single bolus IV dose of 1.0 mg/kg succinylcholine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Single bolus IV dose of 1.2 mg/kg rocuronium
Study: NCT01287117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Study: NCT01720251

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: SC injections of placebo on days 1, 7, 14, 28 and 56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT low dose
Description: SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AllerT full dose
Description: SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
Study: NCT04100525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological testing intervention plus follow up
Description: Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological testing intervention plus follow up
Description: Neuropsychological testing for women experiencing significant fatigue, mood, or cognitive symptoms. Feedback type and case management services varied depending on randomized group.
Study: NCT02277886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium alginate
Description: oral suspension, 50mg/ml, 20ml once at bed time

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: 40mg/tablet, one tablet once before breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: 40mg/tablet, one tablet once before breakfast
Study: NCT01357239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFQ056

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04937257

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality
Description: The training included the following in the specified order: (1) A tutorial with an introduction to the program and a overview of the correct donning and doffing sequence, based on Center for Disease Control (CDC) guidelines, (2) a training mode to practice the correct sequences with step-wise feedback, and (3) a testing mode that repeated until the sequence was completed perfectly without any mistakes. A study member was present to assist with the device and record the duration of training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: E-module
Description: The instructional video included step-by-step instruction and demonstration of adequate donning and doffing procedures. The 14-slide presentation contained the same content as used by the home institution for competency training, based on Center for Disease Control (CDC) guidelines. Participants were instructed to review the material however they liked and their duration of training was recorded.
Study: NCT03484026

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioFe
Description: BioFe Medical Food is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
Study: NCT04471220

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal cannula
Description: The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal cannula
Description: The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal cannula
Description: The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flow nasal cannula
Description: The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
Study: NCT02291341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine Delayed-Release Capsules 60 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cymbalta®
Description: 60 mg capsule of Eli Lilly and Company
Study: NCT01152099

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Bandaging
Description: Group A or Control Group: ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymph Drainage (MLD) and Compression Bandaging
Description: Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.~If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied.
Study: NCT02389881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-058
Description: TAK-058 Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-058
Description: TAK-058 Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-058 Placebo
Description: TAK-058 placebo-matching solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-058 Placebo
Description: TAK-058 placebo-matching solution
Study: NCT00577590

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin is taken alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is taken alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is taken alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: Rosiglitizone is taken with Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: Lovaza is taken with Metformin
Study: NCT03461926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (SB-related planning + daily text messages)
Description: Participants will receive a one-on-one behavioral counseling session, and planning sheet as reference for developing strategies as part of their Action/Coping Plan. Participants will be asked to form 3-4 actions/coping plans specifying when, where, how, and for how long they would reduce workplace sitting time; and anticipate potential barriers and identify ways they could be overcome. Strategies will focus on increasing break frequency to every 30-45 minutes, achieving a break duration of 2-3 minutes, and increasing standing and light-intensity PA time, during work hours. Participants will receive sedentary behaviour-related text messages twice daily, depending on their preferences and schedule, which will act as mini-booster interventions.
Study: NCT03115385

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
Study: NCT00986778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adefovir
Description: Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir
Description: Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
Study: NCT01079923

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single High Dose Cholecalciferol
Description: Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Daily Dose Cholecalciferol
Description: Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
Study: NCT03888495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender Socialization Training workshop
Description: Hands-on training workshops including lectures, group activities, role play and group discussions focused on gender socialization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender Socialization Training workshop
Description: Hands-on training workshops including lectures, group activities, role play and group discussions focused on gender socialization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender Socialization Training workshop
Description: Hands-on training workshops including lectures, group activities, role play and group discussions focused on gender socialization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy Training Intervention
Description: Hands-on training workshops including lectures, group activities, role play and group discussions focused on financial literacy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Literacy Training Intervention
Description: Hands-on training workshops including lectures, group activities, role play and group discussions focused on financial literacy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Planning Counseling and Services
Description: Family planning counseling sessions and linkage to services.
Study: NCT01486238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen® pegaptanib sodium
Description: Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.~Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen® pegaptanib sodium
Description: Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.~Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert.
Study: NCT00152256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: Asoprisnil 10 mg Tablet, oral Daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: Asoprisnil 25mg Tablet, oral Daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablet, oral Daily for 6 months
Study: NCT01568411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-1211
Description: Period 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-1211+ itraconazole
Description: Period 2
Study: NCT00736281

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food Drops: Food Allergens (peptides)
Description: The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
Study: NCT03419702

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds
Description: During the intervention period of 5 months, subjects will receive daily 50 gr almonds. Subjects are free to consume the almonds during the day whenever they want to, i.e. there will not be guidelines when to consume the almonds.
Study: NCT05288465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Patients prescribed for Cerebrolysin treatment due neurological disease are invited to donate a scalp punch biopsy prior to and after completing the prescribed treatment.
Study: NCT02817204

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education
Description: Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
Study: NCT04675281

Intervention type: OTHER
Intervention: 2 post-mortem transcutaneous lung biopsies (1 anterior ; 1 posterior) using anatomical landmarks
Description: All specimens are fixed with 4% neutral formaldehyde and embedded in paraffin wax in the department of pathology of each participating centre. Afterwards, all samples are sent for analysis to the department of pathology of Nantes university hospital. All biopsies are independently analysed by a group of pathologists who are experts in lung tissue and blinded to clinical information. All biopsies will be analysed using a predetermined semi-quantitative histological scoring grid. The pathologists are asked to assess the degree of: edema, cell necrosis, hyaline membrane formation, proliferation of alveolar type 2 cells, fibrosis, capillary congestion, alveolar edema, neutrophilic infiltration, and microscopic thrombosis. Finally, the following patterns are recorded: exudative diffuse alveolar damage (DAD), proliferative DAD, fibrosis, intra-alveolar haemorrhage, lymphocytic pneumonia, organizing pneumonia, acute fibrinous organizing pneumonia (AFOP), thrombotic microangiopathy.
Study: NCT02348047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hamilton T1

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hamilton T1
Study: NCT02233725

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Definity Perflutren Injectable Suspension
Description: a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
Study: NCT01277146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMP-59R5
Description: IV infusion